Navigation Links
ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
Date:12/9/2008

CAMBRIDGE, United Kingdom and MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that its U.K.-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has signed a Long-term Supply Agreement (the "Agreement") with a world-leading European Biopharmaceutical company estimated to be worth up to $35 M over the next six years, with first shipment delivery starting this quarter. This Agreement will provide access to one of ProMetic's proprietary affinity adsorbents for incorporation into this company's manufacturing process.

"This agreement provides further evidence of the underlying growth in the demand for ProMetic's proprietary affinity adsorbents," commented Dr. Steve Burton, PBL's Chief Executive Officer. Dr. Burton added: "Due to reasons of client confidentiality the terms of the Agreement and the name of ProMetic's partner remain undisclosed."

"More and more biopharmaceutical products that have received or are expecting to receive approval from the regulatory agencies such as the Food and Drug Administration or the European Medicines Agency are now manufactured using ProMetic's affinity adsorbent products," stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. "ProMetic's affinity adsorbent products are therefore locked into the regulated manufacturing processes of these biopharmaceuticals and represent long-term recurring and growing annuity revenues for the Company," concluded Mr. Laurin.

About ProMetic BioSciences Ltd

Using its unique and proprietary Mimetic Ligand(TM) technology, ProMetic BioSciences Ltd ("PBL") specializes in the development and manufacture of robust affinity separation materials which provide very high levels of purification. This is achieved by use of small chemical affinity ligands designed to bind a target biomolecule specifically and reversibly. In view of their use for the production of therapeutics, ProMetic's affinity products are manufactured according to a strict quality system based on good manufacturing practice at PBL's ISO 9001:2000 certified manufacturing facility on the Isle of Man, which completed a (pnds stlg)1.5 million expansion in 2005. PBL also operates an R&D laboratory located on the Cambridge Science Park, U.K.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.


'/>"/>
SOURCE Prometic Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProMetic to present at Merriman Curhan Fords Investor Summit 2008 on September 16th
2. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
3. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
4. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
5. Prometic provides information for its Annual and Special Meeting of Shareholders
6. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
7. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
8. Prometic to present at the American Chemical Society
9. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
10. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
11. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):